NewAmsterdam appoints William H. Lewis as Chair of Board, succeeds founder Sander Slootweg

NewAmsterdam Pharma Co N.V.

William H. Lewis, CEO of Insmed since 2012, appointed Chair of NewAmsterdam's Board effective Jan 4, 2024.
He replaces Sander Slootweg (Forbion), Chairman since Company inception.
Lewis receives annual cash retainer $40k + $30k Chair fee + $20k lead director fee; granted 100k share options.
Board increased to ten; Lewis serves as temporary non-executive director until next shareholder meeting.
Lewis appointed to Audit and Compensation Committees; meets Nasdaq independence standards.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sander Slootweg

Chairman of the Board

NAMS · NewAmsterdam Pharma Co N.V.

Effective: 2024-01-04
Successor: Willian H. Lewis
Filed: January 8, 2024, 6:59 PM ET

Mr. Lewis succeeds Sander Slootweg, Managing Partner at Forbion, who has served as Chairman of the Board since inception.

Appointed

Willian H. Lewis

Chair of the Board

NAMS · NewAmsterdam Pharma Co N.V.

Effective: 2024-01-04
Filed: January 8, 2024, 6:59 PM ET

appointed Willian H. Lewis, J.D., M.B.A., as Chair of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sander Slootweg departed as Chairman of the Board at NewAmsterdam Pharma Co N.V..

Action: succeeded
Role: Chairman of the Board

Exact text from the filing

Mr. Lewis succeeds Sander Slootweg, Managing Partner at Forbion, who has served as Chairman of the Board since inception.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Willian H. Lewis was appointed as Chair of the Board at NewAmsterdam Pharma Co N.V..

Action: appointed
Role: Chair of the Board

Exact text from the filing

appointed Willian H. Lewis, J.D., M.B.A., as Chair of the Board.

View on SEC.gov

NewAmsterdam Pharma Co N.V. filing history →

Source: SEC EDGAR

accession 0001193125-24-003956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.